启动或加量不同降尿酸治疗时痛风发作风险比较:系统综述与网状Meta分析
该系统综述与网状Meta分析纳入29篇文献(27项试验),评估成人痛风患者启动或加量不同降尿酸治疗后的痛风发作风险、联用与不联用发作预防的发作风险、预防相关不良事件及最佳预防时长。结果显示,发作风险比(RR)随降尿酸药物和剂量策略而异,秋水仙碱和利纳西普预防可降低发作发生率,关于预防危害和最佳时长的证据有限。
要点
- 与安慰剂联合预防相比,非布司他40 mg联合预防的发作RR为1.08(95%CI 0.87-1.33)。
- 与单用降尿酸治疗相比,联用利纳西普160 mg的发作RR为0.35(95%CI 0.25-0.50)。
- 关于降尿酸治疗加量、其他预防措施、预防危害及最佳时长的证据有限。
核心结论
- 启动降尿酸治疗时的痛风发作RR因降尿酸药物和剂量策略而异。
- 秋水仙碱和利纳西普预防可降低痛风发作发生率。
- 关于预防措施危害和最佳时长的研究仍需开展。
研究设计与样本
- 系统检索Medline、Embase、Web of Science和Cochrane数据库及临床试验注册库,检索时间自建库至2021年11月。
- 纳入成人痛风患者启动或加量降尿酸治疗的试验,共29篇文献(27项试验)。
- 采用随机效应网状Meta分析计算治疗间风险比(RR),使用修订版Cochrane偏倚风险评估工具评估偏倚。
主要发现
- 与安慰剂联合预防相比,非布司他40 mg联合预防的发作RR为1.08(95%CI 0.87-1.33),非布司他80 mg联合来西努拉400 mg联合预防的发作RR为2.65(95%CI 1.58-4.45)。
- 与单用降尿酸治疗相比,联用利纳西普160 mg的发作RR为0.35(95%CI 0.25-0.50),联用利纳西普80 mg的RR为0.43(95%CI 0.31-0.60),联用秋水仙碱的RR为0.50(95%CI 0.35-0.72)。
- 主要因结局数据缺失和报告结果选择偏倚,分别有71.4%和63.4%的研究在发作和不良事件方面被评估为高偏倚风险。
关键数值与推荐
- 与安慰剂联合预防相比,非布司他40 mg联合预防的发作RR为1.08(95%CI 0.87-1.33)。
- 与安慰剂联合预防相比,非布司他80 mg联合来西努拉400 mg联合预防的发作RR为2.65(95%CI 1.58-4.45)。
- 与单用降尿酸治疗相比,联用利纳西普160 mg的发作RR为0.35(95%CI 0.25-0.50),联用利纳西普80 mg的RR为0.43(95%CI 0.31-0.60),联用秋水仙碱的RR为0.50(95%CI 0.35-0.72)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 关于降尿酸治疗加量的数据有限。
- 关于其他发作预防措施、预防危害和最佳时长的证据有限。
- 主要因结局数据缺失和报告结果选择偏倚,71.4%的研究在发作方面、63.4%的研究在不良事件方面被评估为高偏倚风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We systematically examined comparative gout flare risk after initiation or escalation of different urate-lowering therapies (ULTs), comparative flare risk with and without concomitant flare prophylaxis, adverse event rates associated with flare prophylaxis, and optimal duration of flare prophylaxis. METHODS: We searched the Medline, Embase, Web of Science, and Cochrane databases and clinical trial registries from inception to November 2021 for trials investigating adults with gout initiating or escalating ULT. We performed random effects network meta-analyses and calculated risk ratios (RRs) between treatments. Bias was assessed using the revised Cochrane risk-of-bias tool. RESULTS: We identified 3,775 records, of which 29 publications (27 trials) were included. When compared to placebo plus prophylaxis, the RR of flares ranged from 1.08 (95% confidence interval [CI] 0.87-1.33) for febuxostat 40 mg plus prophylaxis to RR 2.65 [95% CI 1.58-4.45] for febuxostat 80 mg plus lesinurad 400 mg plus prophylaxis. Compared to ULT alone, the RR of flares was lower for ULT plus rilonacept 160 mg (RR 0.35 [95% CI 0.25-0.50]), ULT plus rilonacept 80 mg (RR 0.43 [95% CI 0.31-0.60]) and ULT plus colchicine (RR 0.50 [95% CI 0.35-0.72]). There was limited evidence for other flare prophylaxis and on prophylaxis harms and optimal duration. Primarily because of missing outcome data and bias in the selection of reported results, 71.4% and 63.4% of studies were assessed as high risk of bias for flares and adverse events, respectively. CONCLUSION: The RR of flares when introducing ULT varies depending on ULT drug and dosing strategies. There were limited data on ULT escalation. Flare prophylaxis with colchicine and rilonacept reduces flare incidence. More research is required on the harms and optimal duration of prophylaxis.
引用
- Maher D, Reeve E, Hopkins A, et al. Comparative Risk of Gout Flares When Initiating or Escalating Various Urate-Lowering Therapy: A Systematic Review With Network Meta-Analysis. Arthritis Care Res (Hoboken). 2024. PMID: 38303574. doi:10.1002/acr.25309
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。